Tags

Type your tag names separated by a space and hit enter

Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Biochimie 2013; 95(10):1811-27B

Abstract

Several inositol isomers and in particular myo-inositol (MI) and D-chiro-inositol (DCI), were shown to possess insulin-mimetic properties and to be efficient in lowering post-prandial blood glucose. In addition, abnormalities in inositol metabolism are associated with insulin resistance and with long term microvascular complications of diabetes, supporting a role of inositol or its derivatives in glucose metabolism. The aim of this review is to focus on the potential benefits of a dietary supplement of myo-inositol, by far the most common inositol isomer in foodstuffs, in human disorders associated with insulin resistance (polycystic ovary syndrome, gestational diabetes mellitus or metabolic syndrome) or in prevention or treatment of some diabetic complications (neuropathy, nephropathy, cataract). The relevance of such a nutritional strategy will be discussed for each context on the basis of the clinical and/or animal studies. The dietary sources of myo-inositol and its metabolism from its dietary uptake to its renal excretion will be also covered in this review. Finally, the actual insights into inositol insulin-sensitizing effects will be addressed and in particular the possible role of inositol glycans as insulin second messengers.

Authors+Show Affiliations

Université de Lyon, INSA de Lyon, CarMeN, INSERM U1060, Univ Lyon-1, F-69621 Villeurbanne, France. marine.croze@insa-lyon.frNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23764390

Citation

Croze, Marine L., and Christophe O. Soulage. "Potential Role and Therapeutic Interests of Myo-inositol in Metabolic Diseases." Biochimie, vol. 95, no. 10, 2013, pp. 1811-27.
Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811-27.
Croze, M. L., & Soulage, C. O. (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie, 95(10), pp. 1811-27. doi:10.1016/j.biochi.2013.05.011.
Croze ML, Soulage CO. Potential Role and Therapeutic Interests of Myo-inositol in Metabolic Diseases. Biochimie. 2013;95(10):1811-27. PubMed PMID: 23764390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential role and therapeutic interests of myo-inositol in metabolic diseases. AU - Croze,Marine L, AU - Soulage,Christophe O, Y1 - 2013/06/10/ PY - 2013/04/10/received PY - 2013/05/30/accepted PY - 2013/6/15/entrez PY - 2013/6/15/pubmed PY - 2014/3/13/medline KW - 1-d-myo-inositol-phosphate synthase KW - 5′ AMP-activated protein kinase KW - AC KW - ACC KW - AGEs KW - AMP KW - AMPK KW - AUC KW - BMI KW - Body Mass Index KW - CDP-DAG KW - D-chiro-inositol KW - DCI KW - Diabetes KW - Diabetic neuropathy KW - ECM KW - FA KW - FSH KW - G3PAT KW - GFR KW - GK KW - GLUT-4 KW - GMD KW - GPI KW - GS KW - GSK3 KW - Goto Kakizaki (rat) KW - H(+)/myo-inositol transporter KW - HDL KW - HK KW - HMIT KW - HOMA-IR KW - IMPase KW - INS-2 KW - IPG KW - IPs KW - IR KW - IRS KW - Inositol KW - Insulin resistance KW - LD50 KW - LDL KW - LH KW - LysoPI KW - MI KW - MIOX KW - MIPS KW - MNCV KW - MetS KW - Metabolic syndrome KW - OGTT KW - PCOS KW - PDH KW - PDHP KW - PDK KW - PI KW - PI3K KW - PIPs KW - PKA KW - PKB KW - PKC KW - PLC KW - PLD KW - PP-InsPs KW - PP2Cα KW - Polycystic ovary syndrome KW - Protein Kinase B KW - RCT KW - SHBG KW - SHR KW - SMIT1/2 KW - STZ KW - Sex Hormon Binding Globulin KW - acetyl-coenzyme A carboxylase KW - adenosine monophosphate KW - adenylyl cyclase KW - advanced glycation end products KW - area under the curve KW - cAMP KW - cyclic AMP KW - cyclic AMP-dependent protein kinase KW - cytidine diphosphate-diacylglycerol KW - extracellular matrix KW - folic acid KW - follicle-stimulating hormone KW - gestational diabetes mellitus KW - glomerular filtration rate KW - glucose transporter 4 KW - glycerol-3-phosphate acyltransferase KW - glycogen synthase KW - glycogen synthase kinase 3 KW - glycosyl phosphatidylinositol KW - hexokinase KW - high density lipoprotein KW - homeostasis model assessment of insulin resistance KW - inositol monophosphatase KW - inositol phosphates (including in particular: Ins-P: inositol monophosphate, IP3, inositol triphosphates, IP6, inositol hexakisphosphates or phytic acid) KW - inositol phosphoglycan KW - insulin receptor KW - insulin receptor substrate(s) KW - insulin second messenger with a 4-O-(2-amino-2-deoxy-beta-d-galactopyranosyl)-3-O-methyl-d-chiro-inositol structure KW - low density lipoprotein KW - luteinizing hormone KW - lysophosphatidylinositol KW - mTOR KW - mammalian target of rapamycin KW - median lethal dose KW - metabolic syndrome KW - motor nerve conduction velocity KW - myo-inositol KW - myo-inositol oxygenase KW - oral glucose tolerance test KW - phosphatidylinositol KW - phosphatidylinositol phosphate lipids (including PIP(2), phosphatidylinositol 4,5-bisphosphate and PIP(3), phosphatidylinositol (3,4,5)-trisphosphate) KW - phosphatidylinositol-3-kinase(s) KW - phosphoinositide-dependent kinase KW - phospholipase C KW - phospholipase D KW - phosphoprotein phosphatase 2C alpha KW - polycystic ovary syndrome KW - protein kinase C KW - pyrophosphate forms of inositol phosphates KW - pyruvate dehydrogenase KW - pyruvate dehydrogenase phosphatase KW - randomized controlled trial KW - sodium-dependant myo-inositol transporter 1/2 KW - spontaneously hypertensive rat KW - streptozotocin SP - 1811 EP - 27 JF - Biochimie JO - Biochimie VL - 95 IS - 10 N2 - Several inositol isomers and in particular myo-inositol (MI) and D-chiro-inositol (DCI), were shown to possess insulin-mimetic properties and to be efficient in lowering post-prandial blood glucose. In addition, abnormalities in inositol metabolism are associated with insulin resistance and with long term microvascular complications of diabetes, supporting a role of inositol or its derivatives in glucose metabolism. The aim of this review is to focus on the potential benefits of a dietary supplement of myo-inositol, by far the most common inositol isomer in foodstuffs, in human disorders associated with insulin resistance (polycystic ovary syndrome, gestational diabetes mellitus or metabolic syndrome) or in prevention or treatment of some diabetic complications (neuropathy, nephropathy, cataract). The relevance of such a nutritional strategy will be discussed for each context on the basis of the clinical and/or animal studies. The dietary sources of myo-inositol and its metabolism from its dietary uptake to its renal excretion will be also covered in this review. Finally, the actual insights into inositol insulin-sensitizing effects will be addressed and in particular the possible role of inositol glycans as insulin second messengers. SN - 1638-6183 UR - https://www.unboundmedicine.com/medline/citation/23764390/Potential_role_and_therapeutic_interests_of_myo_inositol_in_metabolic_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0300-9084(13)00158-2 DB - PRIME DP - Unbound Medicine ER -